{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:25:41Z","timestamp":1787757941533,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"abstract":"\n Context:<\/jats:title>\n When cure is possible treatment should be undertaken despite life-threatening toxicities. Fluorouracil-Adriamycin-Cyclophosphamide (FAC) and Adriamycin-Cyclophosphamide (AC-P) are two popular regimens used in the treatment of carcinoma breast and the data regarding the toxicity profile of the AC-P regimen is scarce in the South Indian population.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n To study the severity of different types of toxicities seen in patients on FAC and AC-P regimens, to grade the toxicity according to the World Health Organization (WHO) toxicity grading, and to compare the same. Settings and Design: A prospective observational study, with 50 patients in each regimen, was conducted in the Department of Radiotherapy between February 2007 and July 2008.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n The high risk patients received the AC-P regimen and the rest received the FAC regimen. The toxicities developed were graded according to the WHO guidelines.<\/jats:p>\n <\/jats:sec>\n \n Statistical Analysis Used:<\/jats:title>\n The data was analyzed using the chi square test in SPSS 16.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Anemia, hyperpigmentation, stomatitis, and diarrhea were significantly high (\n P<\/jats:italic>\n < 0.05) in patients receiving the FAC regimen, whereas, leukopenia, myalgia, arthralgia and peripheral neuropathy were significantly high (\n P<\/jats:italic>\n <0.05) in patients receiving the AC-P regimen. The Karnofsky performance status was higher in patients receiving the AC-P regimen.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Although both the regimens had different toxicity profiles the quality of life was better for patients on the AC-P regimen.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0019-509x.75836","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T08:30:29Z","timestamp":1295857829000},"page":"68-73","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast"],"prefix":"10.4103","volume":"48","author":[{"given":"Dhanya S","family":"Palappallil","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Government Medical College, Kottayam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu Latha R","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Government Medical College, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KL","family":"Jayakumar","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Government Medical College, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramani T","family":"Puvathalil","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Government Medical College, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2011,2,10]]},"reference":[{"key":"R1-20260604","first-page":"222","article-title":"Cancer risk and diet in India","volume":"49","author":"Sinha","year":"2003","journal-title":"J Postgrad Med"},{"key":"R2-20260604","first-page":"1","volume":"17","year":"2000","journal-title":"NIH Consensus Statement Online"},{"key":"R4-20260604","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: Reliability, validity, and guidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J Clin Oncol"},{"key":"R5-20260604","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"R6-20260604","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node- positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-20260604","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1477-7819-5-56","article-title":"Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India","volume":"5","author":"Kuraparthy","year":"2007","journal-title":"World J Surg Oncol"},{"key":"R8-20260604","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000089991","article-title":"Five-year update of an expanded phase II study of dose-dense and intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer","volume":"69","author":"Abu-Khalaf","year":"2005","journal-title":"Oncology"},{"key":"R9-20260604","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.1979.03300140025017","article-title":"Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide and BCG vaccine: A follow up report","volume":"242","author":"Buzdar","year":"1979","journal-title":"JAMA"},{"key":"R10-20260604","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","article-title":"Dose and dose intensity of adjuvant chemotherapy for stage II, node- positive carcinoma breast","volume":"330","author":"Wood","year":"1994","journal-title":"N Engl J Med"},{"key":"R11-20260604","first-page":"224","article-title":"Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting","volume":"5","author":"Burtness","year":"1999","journal-title":"Cancer J Sci Am"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223310-201148010-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:00:11Z","timestamp":1787756411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223310-201148010-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.4103\/0019-509x.75836","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}